MX2014013566A - Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases. - Google Patents
Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases.Info
- Publication number
- MX2014013566A MX2014013566A MX2014013566A MX2014013566A MX2014013566A MX 2014013566 A MX2014013566 A MX 2014013566A MX 2014013566 A MX2014013566 A MX 2014013566A MX 2014013566 A MX2014013566 A MX 2014013566A MX 2014013566 A MX2014013566 A MX 2014013566A
- Authority
- MX
- Mexico
- Prior art keywords
- hyperammonemia
- acute
- hepatic encephalopathy
- vitro
- gene therapy
- Prior art date
Links
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure is related to the production of a new drug for the treatment of Hepatic Encephalopathy (HE), which consists of recombinant viruses, in particular baculoviruses, which over-expresses one or more of the ammonia metabolism enzymes including Glutamine synthetase (GS), in various tissues of the patient and with the purpose of reducing the acute hyperammonemia and relief the signs and symptoms of HE. The recombinant baculovirus Bac-GS developed in the present invention expresses the RNAm and the GS and, as a result, reduces the levels of ammonium in the in-vitro and in-vivo medium. For this purpose, a new in-vitro hyperammonemia model was generated. This new drug called Bac-GS can be used to reduce acute hyperammonemia in patients with urea cycle disorders and other diseases with high ammonia levels, such as: acute and chronic liver failure, hepatocellular carcinoma and diseases related to neuropsychiatric disorders.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014013566A MX2014013566A (en) | 2014-11-07 | 2014-11-07 | Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014013566A MX2014013566A (en) | 2014-11-07 | 2014-11-07 | Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014013566A true MX2014013566A (en) | 2016-05-09 |
Family
ID=56797787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014013566A MX2014013566A (en) | 2014-11-07 | 2014-11-07 | Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases. |
Country Status (1)
Country | Link |
---|---|
MX (1) | MX2014013566A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020065082A1 (en) * | 2018-09-28 | 2020-04-02 | Thoeris Gmbh | Use of glutamine synthetase for treating fatty liver disease |
US11932885B2 (en) | 2017-05-24 | 2024-03-19 | Thoeris Gmbh | Use of glutamine synthetase for treating hyperammonemia |
-
2014
- 2014-11-07 MX MX2014013566A patent/MX2014013566A/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11932885B2 (en) | 2017-05-24 | 2024-03-19 | Thoeris Gmbh | Use of glutamine synthetase for treating hyperammonemia |
WO2020065082A1 (en) * | 2018-09-28 | 2020-04-02 | Thoeris Gmbh | Use of glutamine synthetase for treating fatty liver disease |
CN113474003A (en) * | 2018-09-28 | 2021-10-01 | 托埃瑞斯有限责任公司 | Use of glutamine synthetase for treating fatty liver disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
MX2023012450A (en) | Esketamine for the treatment of depression. | |
PH12017500746A1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
BR112015005227A2 (en) | glycosylceramide synthase inhibitors | |
MX2018015089A (en) | Combinations of linagliptin and metformin. | |
BR112015007616A2 (en) | mek inhibitors in the treatment of virus diseases | |
MX2023000796A (en) | Pharmaceutical composition, methods for treating and uses thereof. | |
PH12018501443A1 (en) | Methods of administering hepcidin | |
BR112015022907A2 (en) | (s) -quinuclidin-3-yl (2- (2- (4-fluorophenyl) thiazol-4-yl) propan-2-yl) carbamate salt forms | |
MX2016000220A (en) | Regulation of glucose metabolism using anti-cgrp antibodies. | |
EA201991175A1 (en) | THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS | |
BR112018067554A2 (en) | testosterone formulations and treatment methods with them | |
PH12017501304A1 (en) | Levodopa and carbidopa intestinal gel and method of use | |
MX2014013566A (en) | Gene therapy to treat hyperammonemia in hepatic encephalopathy and other liver diseases. | |
PH12019501358A1 (en) | Methods of administering hepcidin | |
UA111116C2 (en) | Balanced infusion solution | |
NZ705229A (en) | Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity | |
MD596Y (en) | Method for treating the chronic viral hepatitis C | |
Micheli | Piribedil/pramipexole/ropinirole | |
EA201990676A1 (en) | OSTEOARTHRITIS TREATMENT | |
EA201892048A1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING EMAGAGLIFLOZIN, AND ITS APPLICATIONS | |
Hahn | Diarrhoea: case report | |
UA114982U (en) | METHOD OF TREATMENT OF PATIENTS WITH CHRONIC PURPLE EXTREMELY SYNUIT WITH TYPE 1 DIABETES | |
UA104030U (en) | Method for treating patients with acute condition of chronic bronchitis of viral etiology |